to oversee manufacturer compliance with such section 340B of the Public Health Service Act ( 42 U.S.C. 256b ). (3) There is no public transparency on drug manufacturers’ average manufacturer price, best price in the marketplace, or how much the average manufacturer price of a drug has increased relative to the rate of inflation. (4) Information on the average manufacturer price and best price are reported to the Centers for Medicare & Medicaid Services, but rarely does the Federal Government audit the raw data underlying those calculations. (5) Such data is not submitted and reviewed by the Health Resources and Services Administration as part of a 340B program audit. (6) Furthermore, the Office of Pharmacy Affairs has conducted only 11 total audits of manufacturers. (b) Parity in audits between manufacturer and hospital audits Section 340B(d)(1)(B)(v) of the Public Health Service Act ( 42 U.S.C. 256b(d)(1)(B)(v) ) is amended to read as follows: (v) Selective auditing of manufacturers and wholesalers to ensure the integrity of the drug discount program under this section, consistent with the following: (I) Such audits shall be conducted in a form and manner that, to the greatest extent practicable, results in parity between such audits and audits under subsection (a)(5)(C) of covered entities, as measured by comparing the percentage of total manufacturer audits under this clause to the percentage of total audits conducted under such subsection of covered entities described in subsection (a)(4)(L). (II) Such audits shall include review of average manufacturer price, best price, and the inflationary penalty to ensure that manufacturers are calculating the ceiling price accurately. . (c) Deadline for Internet Website with applicable ceiling prices for covered outpatient drugs Section 340B(d)(1)(B)(iii) of the Public Health Service Act ( 42 U.S.C. 256b(d)(1)(B)(iii) ) is amended by striking The provision and inserting Not later than 90 days after the date of the enactment of the Stretching Entity Resources for